CVRx to Participate at the Piper Sandler 37th Annual Healthcare Conference
CVRx (NASDAQ: CVRX) announced its management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, Dec. 3, 2025.
The session is scheduled for 2:00 p.m. ET and will be available via a live audio webcast on the company investor relations website at ir.cvrx.com. The presentation offers investors a chance to hear management discuss recent developments and company outlook.
CVRx (NASDAQ: CVRX) ha annunciato che il suo team di gestione parteciperà a un dibattito informale durante la Piper Sandler 37th Annual Healthcare Conference il mercoledì 3 dicembre 2025.
La sessione è prevista per le 14:00 ET e sarà disponibile tramite una webcast audio in diretta sul sito di relazioni con gli investitori dell'azienda all'indirizzo ir.cvrx.com. La presentazione offre agli investitori l'opportunità di ascoltare la direzione discutere degli sviluppi recenti e delle prospettive della società.
CVRx (NASDAQ: CVRX) anunció que su equipo de dirección participará en una charla casual en la Piper Sandler 37th Annual Healthcare Conference el miércoles 3 de diciembre de 2025.
La sesión está programada para las 2:00 p.m. ET y estará disponible a través de una webcast de audio en vivo en el sitio web de relaciones con inversores de la empresa en ir.cvrx.com. La presentación ofrece a los inversores la oportunidad de escuchar a la dirección discutir los desarrollos recientes y las perspectivas de la empresa.
CVRx (NASDAQ: CVRX)는 경영진이 Piper Sandler 37th Annual Healthcare Conference의 파이어사이드 채팅에 참여할 예정이라고 발표했습니다. 2025년 12월 3일 수요일에 개최됩니다.
세션은 미 동부 표준시 2:00 PM에 예정되어 있으며 회사의 투자자 관계 웹사이트 ir.cvrx.com에서 생방송 오디오 웹캐스트를 통해 이용 가능할 것입니다. 발표는 투자자들에게 최근 개발 상황과 회사의 전망에 대해 경영진이 논의하는 자리를 제공합니다.
CVRx (NASDAQ: CVRX) a annoncé que son équipe de direction participera à une discussion informelle lors de la Piper Sandler 37th Annual Healthcare Conference le mercredi 3 décembre 2025.
La session est prévue à 14h00 HNE et sera disponible via une webcast audio en direct sur le site des relations investisseurs de l'entreprise à l'adresse ir.cvrx.com. La présentation offre aux investisseurs l'occasion d'entendre la direction discuter des développements récents et des perspectives de l'entreprise.
CVRx (NASDAQ: CVRX) gab bekannt, dass das Management-Team an einem Fireside-Chat auf der Piper Sandler 37th Annual Healthcare Conference am Mittwoch, dem 3. Dezember 2025 teilnehmen wird.
Die Sitzung ist für 14:00 Uhr ET vorgesehen und wird per Live-Audio-Webcast auf der Investor-Relations-Website des Unternehmens unter ir.cvrx.com verfügbar sein. Die Präsentation gibt Investoren die Möglichkeit, von der Geschäftsführung über jüngste Entwicklungen und die Aussichten des Unternehmens zu hören.
CVRx (NASDAQ: CVRX) أعلنت أن فريق الإدارة سيشارك في دردشة موقدة حوارية خلال Piper Sandler 37th Annual Healthcare Conference في الأربعاء 3 ديسمبر 2025.
الجلسة مقررة لـ 2:00 مساءً بتوقيت شرق الولايات المتحدة وستكون متاحة عبر بث صوتي مباشر عبر موقع علاقات المستثمرين بالشركة على ir.cvrx.com. تقدم العروض للمستثمرين فرصة لسماع الإدارة وهي تناقش التطورات الأخيرة وآفاق الشركة.
- None.
- None.
MINNEAPOLIS, Nov. 19, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, Dec. 3, 2025. The fireside chat is scheduled at 2:00 p.m. (ET) the same day via webcast.
A live audio webcast of the fireside chat will be available online at the investor relations page of the Company’s website at ir.cvrx.com.
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com
Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com
FAQ
When will CVRx (CVRX) present at the Piper Sandler 37th Annual Healthcare Conference?
How can investors listen to the CVRx (CVRX) fireside chat on Dec. 3, 2025?
What topics will CVRx (CVRX) management likely cover in the Piper Sandler fireside chat?
Is the CVRx (CVRX) Piper Sandler presentation open to the public or only to conference attendees?
Where can I find the replay of the CVRx (CVRX) Piper Sandler fireside chat after Dec. 3, 2025?
